Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England

H. H. Webster, T. Nyberg, M. A. Sinnathamby, N. Abdul Aziz, N. Ferguson, G. Seghezzo, P. B. Blomquist, J. Bridgen, M. Chand, N. Groves, R. Myers, R. Hope, E. Ashano, J. Lopez-Bernal, D. Angelis, G. Dabrera, A. M. Presanis and S. Thelwall ()
Additional contact information
H. H. Webster: UKHSA COVID-19 National Epidemiology Cell
T. Nyberg: University of Cambridge
M. A. Sinnathamby: UKHSA COVID-19 National Epidemiology Cell
N. Abdul Aziz: UKHSA COVID-19 National Epidemiology Cell
N. Ferguson: Imperial College London
G. Seghezzo: UKHSA COVID-19 National Epidemiology Cell
P. B. Blomquist: UKHSA Outbreak Surveillance Team
J. Bridgen: UKHSA Outbreak Surveillance Team
M. Chand: UKHSA Genomics and Public Health Analysis
N. Groves: UKHSA Genomics and Public Health Analysis
R. Myers: UKHSA Genomics and Public Health Analysis
R. Hope: UKHSA COVID-19 National Epidemiology Cell
E. Ashano: UKHSA HCAI, Fungal, AMR, AMU & Sepsis Division
J. Lopez-Bernal: UKHSA COVID-19 Surveillance Cell
D. Angelis: University of Cambridge
G. Dabrera: UKHSA COVID-19 National Epidemiology Cell
A. M. Presanis: University of Cambridge
S. Thelwall: UKHSA COVID-19 National Epidemiology Cell

Nature Communications, 2022, vol. 13, issue 1, 1-6

Abstract: Abstract The Omicron variant of SARS-CoV-2 became the globally dominant variant in early 2022. A sub-lineage of the Omicron variant (BA.2) was identified in England in January 2022. Here, we investigated hospitalisation and mortality risks of COVID-19 cases with the Omicron sub-lineage BA.2 (n = 258,875) compared to BA.1 (n = 984,337) in a large cohort study in England. We estimated the risk of hospital attendance, hospital admission or death using multivariable stratified proportional hazards regression models. After adjustment for confounders, BA.2 cases had lower or similar risks of death (HR = 0.80, 95% CI 0.71–0.90), hospital admission (HR = 0.88, 95% CI 0.83–0.94) and any hospital attendance (HR = 0.98, 95% CI 0.95–1.01). These findings that the risk of severe outcomes following infection with BA.2 SARS-CoV-2 was slightly lower or equivalent to the BA.1 sub-lineage can inform public health strategies in countries where BA.2 is spreading.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-022-33740-9 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-33740-9

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-33740-9

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().